Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
0.465
-0.065 (-12.23%)
At close: Mar 10, 2025, 4:00 PM
0.472
+0.007 (1.55%)
After-hours: Mar 10, 2025, 7:56 PM EST
Amarin Corporation Employees
Amarin Corporation had 275 employees as of December 31, 2023. The number of employees decreased by 90 or -24.66% compared to the previous year.
Employees
275
Change (1Y)
-90
Growth (1Y)
-24.66%
Revenue / Employee
$876,440
Profits / Employee
-$143,076
Market Cap
191.35M
Employees Chart
Employees History
AMRN News
- 11 days ago - Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering - GlobeNewsWire
- 19 days ago - Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 - GlobeNewsWire
- 3 months ago - Amarin Receives National Reimbursement for VAZKEPA® in Italy - GlobeNewsWire
- 3 months ago - Amarin Appoints Peter Fishman Chief Financial Officer - GlobeNewsWire
- 3 months ago - Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
- 4 months ago - Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting - GlobeNewsWire
- 7 months ago - Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress - GlobeNewsWire